Vanda Pharmaceuticals

This study tested a new drug called imsidolimab (ANB019) in 59 adults with palmoplantar pustulosis, a skin condition causing painful pus-filled blisters on hands and feet. The goal was to see if the drug safely reduces symptoms compared to a placebo. The trial is complete, and re…

This study tested whether a new drug, VHX-896, works like the existing drug iloperidone in 26 adults with schizophrenia or bipolar I disorder. Participants took both drugs in a crossover design to compare how the body processes them. The goal was to check if VHX-896 is a safe and…

This study tested a new drug called imsidolimab in 45 adults with generalized pustular psoriasis (GPP), a rare and serious skin condition that causes painful pus-filled bumps. Participants received either the drug or a placebo to see if the drug could clear or nearly clear their …

This study tested a drug called imsidolimab in 8 adults with active generalized pustular psoriasis (GPP), a rare and serious skin disease. The goal was to see if the drug could improve skin symptoms and reduce pustules. Results showed that most participants had meaningful improve…

This study tested a new medication called imsidolimab for people with moderate to severe acne. 123 participants received either the drug or a placebo to see if it reduced acne lesions on the face over 12 weeks. The goal was to find a safer or more effective treatment option for a…

This study tested whether tradipitant can reduce nausea and vomiting caused by GLP-1 receptor agonist drugs (like Ozempic or Wegovy) in 124 healthy overweight or obese volunteers. Participants received either tradipitant or a placebo, and tracked their symptoms daily. The goal wa…

This study tested whether a new eye drop called VSJ-110 can safely reduce eye itching and redness caused by allergies. 47 adults received either the eye drop or a placebo, then were exposed to an allergen. The main goals were to measure changes in itching and redness after exposu…

This study tested a drug called imsidolimab in 149 people with hidradenitis suppurativa, a chronic skin condition causing painful lumps. Participants received either the drug or a placebo for 16 weeks. The main goal was to see if the drug reduced the number of abscesses and infla…